Oryzon Genomics S.A. (BME:ORY)
2.940
+0.022 (0.75%)
Aug 7, 2026, 12:56 PM CET
Oryzon Genomics Employees
Oryzon Genomics had 46 employees as of December 31, 2025. The number of employees decreased by 1 or -2.13% compared to the previous year.
Employees
46
Change
-1
Growth
-2.13%
Revenue / Employee
€334,939
Profits / Employee
€52,791
Market Cap
239.17M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 46 | -1 | -2.13% |
| Jun 30, 2025 | 47 | - | - |
| Dec 31, 2024 | 47 | 1 | 2.17% |
| Dec 31, 2023 | 46 | 2 | 4.78% |
| Dec 31, 2022 | 44 | 0 | - |
| Dec 31, 2021 | 44 | 1 | 1.15% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Grifols | 25,000 |
| Faes Farma | 2,681 |
| Laboratorios Farmaceuticos Rovi | 2,470 |
| Almirall | 2,097 |
| Clínica Baviera | 1,910 |
| Laboratorio Reig Jofre | 1,400 |
| Prim, S.A. | 984 |
| Atrys Health | 758 |
Oryzon Genomics News
- 10 days ago - Oryzon Q2 Net Loss Narrows; Vafidemstat Advances Towards Phase III Trial In BPD Aggression - Nasdaq
- 10 days ago - Oryzon Genomics Earnings release: Q2 2026 - Filings
- 4 weeks ago - Oryzon Genomics Secures U.S. Patent For Vafidemstat In Borderline Personality Disorder - Nasdaq
- 2 months ago - Oryzon Genomics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 3 months ago - ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026 - GlobeNewsWire
- 3 months ago - Oryzon Genomics Earnings release: Q1 2026 - Filings
- 3 months ago - ORYZON to Present Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia at EHA 2026 - GlobeNewsWire
- 5 months ago - Oryzon Genomics announces patent grant decision in Mexico - TheFly